Repositioning of existing clinical drugs to reverse the metabolic reprogramming of SARS-CoV-2 infected patients.
Viral infection reprograms the cellular metabolism of those infected to provide viruses with the energy and resources needed to generate new viral particles.
The study of the metabolic reprogramming of infected patients should serve as (i) an indicator of the evolution of the infection and (ii) to evaluate the efficacy of specific drugs that can reverse the reprogramming of cell metabolism, these being potential antiviral agents and would involve the repositioning of drugs for clinical use.
Principal Investigator: Eduardo Rial (CIB)
